Search for: "C & S Company, Inc." Results 5681 - 5700 of 7,900
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
18 Aug 2011, 10:48 am by NFS Esq.
HAMILTON MEATS & PROVISIONS, INC., Defendant and Respondent. [read post]
18 Aug 2011, 5:00 am by Bexis
& C. 4th 250, 266-67 (Pa. [read post]
17 Aug 2011, 2:00 am by Kara OBrien
Second, the Plaintiffs seek additional details regarding the financial advisors’ analyses such as the reasons why different companies were selected for each advisor’s comparable company analysis or information regarding how the advisors arrived at the multiples they used for those comparable companies. [read post]
16 Aug 2011, 5:30 am by Guest Contributor
A large part of an in-house counsel’s job is helping the company drive revenue and working closely with Sales management and the field. [read post]
16 Aug 2011, 4:00 am by McNabb Associates, P.C.
" According to the Information, a Complaint previously filed in this case, other court filings, and statements made during today's guilty plea proceeding: During the period of the insider trading scheme, SKOWRON was responsible for the Hedge Fund's investment decisions in public companies, including the biopharmaceutical company Human Genome Sciences, Inc. [read post]
16 Aug 2011, 4:00 am by McNabb Associates, P.C.
" According to the Information, a Complaint previously filed in this case, other court filings, and statements made during today's guilty plea proceeding: During the period of the insider trading scheme, SKOWRON was responsible for the Hedge Fund's investment decisions in public companies, including the biopharmaceutical company Human Genome Sciences, Inc. [read post]
14 Aug 2011, 4:01 pm by www.LowerWC.com
Best. www.safetynational.com     Advisen’s data, analytics and news offerings are game-changers for 100,000 commercial P&C professionals. [read post]
11 Aug 2011, 8:56 pm by WOLFGANG DEMINO
[c]ash paid to Ramos" in the amount of "$91,201 (subject to Eva Ramos release). [read post]
11 Aug 2011, 5:25 pm by FDABlog HPM
”  In APP’s First Amended Answers and Counterclaims to The Medicines Companys Complaint for each patent (here and here), APP seeks declaratory and injunctive relief pursuant to FDC Act §505(j)(5)(C), among other statutory provisions. [read post]